Title
Category
Credits
Event date
Cost
  • Behavioral health
  • Disease management
  • Palliative care and hospice
  • 2.00 AMA - Physicians
  • 2.00 ANCC - Nurses
  • 2.00 Attendance - General Attendance
$0.00
Activity descriptionConversations that provide patients who have serious and life-threatening illnesses with the opportunity to make informed choices reflecting their goals, values and care preferences are a critical part of their care. These discussions can help ensure that seriously ill patients receive care that is consistent with their wishes and provide guidance to enhance family well-being and improve the patient’s quality of life.
  • Disease management
  • Vision
  • 1.00 AMA - Physicians
  • 1.00 Attendance - General Attendance
  • 1.00 COPE - Optometrists
$0.00
This activity will explore updated approaches to the management of glaucoma—the “silent thief of sight” that affects an estimated 3 million Americans. It will examine the latest evidence from recent studies on minimally invasive glaucoma surgery (MIGS) procedures and discuss comparative data on more invasive surgical techniques such as trabeculectomy and tube shunt surgery. Patient cases will be introduced to enhance participants’ understanding of the glaucoma treatment process. In addition, potential future innovations in glaucoma treatment will be discussed.
  • Case management
  • 0.50 ANCC - Nurses
  • 0.50 Attendance - General Attendance
  • 0.50 CCMC - General - Case Managers
  • 0.50 ASWB - Social Workers
$0.00
This activity will provide participants with an overview clarifying the dynamics by which the business of health care is affected by the processes of capturing a patient’s reason for their visit and the care provided in response. With a focus on accurate coding that justifies patient services or procedures performed by the provider, it will examine the role of diagnostic-related group (DRG) classifications in payment determination under the inpatient prospective payment system (IPPS), payment systems, ICD-10 coding requirements and payer criteria. The roles of revenue cycles, payer methodologies and patient access in the business of health care will also be examined.
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 ADA - CERP (Dentists/Allied Dental Staff)
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
Join this session to explore updates in genetic therapy for two prevalent hemaglobinopathies: sickle cell disease and beta thalassemia.
  • Disease management
  • Transplantation
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
Patients who have received an organ transplant can provide valuable insights into the entire transplant journey, bringing new awareness to the physical, emotional, and psychological aspects of the transplant journey.
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
The potential consequences of medical misinformation on public health, such as the spread of vaccine hesitancy, will be discussed, and participants will come away empowered with additional strategies and tools to more effectively address medical misinformation and promote accurate health information to patients and the wider community.
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 ADA - CERP (Dentists/Allied Dental Staff)
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will focus on enhancing our understanding of the current opioid crisis and will explore new angles and address current concerns, including the use of over-the-counter intranasal naloxone, the evolving landscape of opioids with a focus on fentanyl, the intersection between suicide and opioid overdoses, the significance of the new 988 helpline in the crisis, and the viability of home-based detox startups. Strategies to effectively address the ongoing challenges of the opioid crisis will be discussed.
  • Vision
  • 1.00 AMA - Physicians
  • 1.00 Attendance - General Attendance
  • 1.00 COPE - Optometrists
$0.00
This on-demand webcast is designed as a comprehensive course for optometrists aimed at demystifying the use of laser technology in eye care; it will cover key laser types, their clinical roles, procedural insights and management of associated complications. The content is geared towards empowering optometrists with the knowledge to confidently apply laser treatments and collaborate effectively in patient care for enhanced outcomes.
  • Disease management
  • Global
  • Nursing
  • 7.00 ANCC - Nurses
  • 7.00 Attendance - General Attendance
  • 9.00 PRC - Philippine Council of Nursing
$0.00
These comprehensive activities will equip nurses with knowledge that will improve patient care in alignment with the standards of care delivery in US health care practices.
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 PRC - Philippine Council of Nursing
  • 1.00 ASWB - Social Workers
$0.00
This activity discusses the current prevalence trends for CRC, new insight into risk factors, recommended screening approaches and modalities, treatment updates focused on tumor-specific molecular targets, and recent and emerging findings in CRC research and clinical trials.

Pages